We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The FDA has approved an expanded label for GlaxoSmithKline’s new Trelegy Ellipta inhaler, allowing it to be used in a broader population of patients with chronic obstructive pulmonary disease (COPD).